Vanta Bioscience Ltd - 540729 - Impact Of Covid 19 On Vanta Bioscience Limited
Impact of Covid 19 on Vanta Bioscience Limited22-05-2020
22-05-2020
Vanta Bioscience Ltd - 540729 - Compliance Certificate Under Reg 40(9) For The Half Year Ended March 31, 2020
Compliance Certificate under Reg 40(9) for the half year ended March 31, 202022-05-2020
Vanta Bioscience Ltd - 540729 - Shareholding for the Period Ended March 31, 2020
Vanta Bioscience Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here29-04-2020
Vanta Bioscience Ltd - 540729 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Zoheb SayaniDesignation :- Company Secretary and Compliance Officer11-04-2020
Vanta Bioscience Ltd - 540729 - Closure of Trading Window
As per the provisions of the code of conduct and policies for prevention of Insider Trading for the Company, the trading window for transactions in the shares of the Company for all designated persons and their immediate relatives will be closed from April 01, 2020 till 48 hours after the declaration of audited financial results of the Company for the year ended March 31, 2020. The date of Board Meeting for consideration of audited financial results of the Company for the year ended March 31, 2020 shall be intimated in due course of time. This is for your information and dissemination to general public.31-03-2020
Vanta Bioscience Ltd - 540729 - Outcome Of Board Meeting Held On 10.03.2020
We wish to inform you that the Board Directors of the Company, at their just concluded meeting have inter alia, transacted the following businesses: 1. Approved the re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as the Managing Director of the Company for a period of 3 years w.e.f April 18, 2020, subject to ratification by members. 2. Approved the re-appointment of Dr. Vyasmurti Madhavrao Shingatgeri (DIN: 07728757) as the Whole Time Director of the Company for a period of 3 years w.e.f April 01, 2020, subject to ratification by members. 3. Approved the appointment of Tapasvilal Deora & Associates, Practising Company Secretaries as Secretarial Auditors of the Company for three years from FY 2020-2110-03-2020
Vanta Bioscience Ltd - 540729 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Zoheb SayaniDesignation :- Company Secretary and Compliance Officer07-01-2020
Vanta Bioscience Ltd - 540729 - Intimation Regarding NABL Accreditation To The Company'S Facility
The Company''s facility has been granted accreditation by NABL in the discipline of Biological testing under the groups Toxicology and Veterinary Testing.04-12-2019
Vanta Bioscience Ltd - 540729 - Outcome Of Board Meeting Dated 13.11.2019
Approved the un audited financial statements for the half year ended 30.09.201913-11-2019